title: Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.
abstract: OBJECTIVE
  To compare the efficacy and safety of subcutaneous (SC) and intravenous (IV) abatacept.
  
  
  METHODS
  In this phase IIIb double-blind, double-dummy, 6-month study, patients with rheumatoid arthritis (RA) and inadequate responses to methotrexate were randomized to receive 125 mg SC abatacept on days 1 and 8 and weekly thereafter (plus an IV loading dose [∼10 mg/kg] on day 1) or IV abatacept (∼10 mg/kg) on days 1, 15, and 29 and every 4 weeks thereafter. The primary end point for determining the noninferiority of SC abatacept to IV abatacept was the proportion of patients in each group meeting the American College of Rheumatology 20% improvement criteria (achieving an ACR20 response) at month 6. Other efficacy end points, immunogenicity, and safety were also assessed.
  
  
  RESULTS
  Of 1,457 patients, 693 of 736 (94.2%) treated with SC abatacept and 676 of 721 (93.8%) treated with IV abatacept completed 6 months. At month 6, 76.0% (95% confidence interval 72.9, 79.2) of SC abatacept-treated patients versus 75.8% (95% confidence interval 72.6, 79.0) of IV abatacept-treated patients achieved an ACR20 response (estimated difference between groups 0.3% [95% confidence interval -4.2, 4.8]), confirming noninferiority of SC abatacept to IV abatacept. Onset and magnitude of ACR responses and disease activity and physical function improvements were comparable between the SC and IV abatacept-treated groups. The proportions of adverse events (AEs) and serious AEs over 6 months were 67.0% and 4.2%, respectively, in the SC abatacept-treated group and 65.2% and 4.9%, respectively, in the IV abatacept-treated group, with comparable frequencies of serious infections, malignancies, and autoimmune events between groups. SC injection site reactions (mostly mild) occurred in 19 SC abatacept (IV placebo)-treated patients (2.6%) and 18 IV abatacept (SC placebo)-treated patients (2.5%). Abatacept-induced antibodies occurred in 1.1% of SC abatacept-treated patients and 2.3% of IV abatacept-treated patients.
  
  
  CONCLUSIONS
  SC abatacept provides efficacy and safety comparable with that of IV abatacept, with low immunogenicity and high retention rates, consistent with the established IV abatacept profile. Rates of injection site reactions were low. SC abatacept will provide additional treatment options, such as an alternative route of administration, for patients with RA.
authors: Stanford University, Palo Alto, California 94304, USA. Genovese@stanford.edu
authors: M C
authors: MC
authors: Genovese
authors: A
authors: A
authors: Covarrubias
authors: G
authors: G
authors: Leon
authors: E
authors: E
authors: Mysler
authors: M
authors: M
authors: Keiserman
authors: R
authors: R
authors: Valente
authors: P
authors: P
authors: Nash
authors: J A
authors: JA
authors: Simon-Campos
authors: W
authors: W
authors: Porawska
authors: J
authors: J
authors: Box
authors: C
authors: C
authors: Legerton
authors: E
authors: E
authors: Nasonov
authors: P
authors: P
authors: Durez
authors: R
authors: R
authors: Aranda
authors: R
authors: R
authors: Pappu
authors: I
authors: I
authors: Delaet
authors: J
authors: J
authors: Teng
authors: R
authors: R
authors: Alten
references: J Rheumatol. 1993 Mar;20(3):557-60
references: 8478873
references: Ann Rheum Dis. 2008 Apr;67(4):547-54
references: 17921185
references: Arthritis Rheum. 2005 Aug;52(8):2263-71
references: 16052582
references: Ann Rheum Dis. 2009 Nov;68(11):1739-45
references: 19019895
references: Stat Med. 2003 Jan 30;22(2):169-86
references: 12520555
references: N Engl J Med. 2005 Sep 15;353(11):1114-23
references: 16162882
references: BMJ. 1991 Aug 3;303(6797):288
references: 1888931
references: Ann Rheum Dis. 2006 Nov;65(11):1478-83
references: 16464988
references: Arthritis Rheum. 1992 May;35(5):498-502
references: 1575785
references: N Engl J Med. 2003 Nov 13;349(20):1907-15
references: 14614165
references: J Rheumatol. 2007 Dec;34(12):2365-73
references: 18050376
references: Arthritis Rheum. 2008 Apr;58(4):953-63
references: 18383390
references: Arthritis Rheum. 1995 Jun;38(6):727-35
references: 7779114
references: Ann Rheum Dis. 2008 Aug;67(8):1096-103
references: 18055472
references: J Rheumatol. 2009 Apr;36(4):736-42
references: 19273451
references: Arthritis Rheum. 1980 Feb;23(2):137-45
references: 7362664
references: Ann Rheum Dis. 2010 Mar;69(3):510-6
references: 19933744
references: Ann Rheum Dis. 2009 Dec;68(12):1870-7
references: 19124524
references: Arthritis Rheum. 1988 Mar;31(3):315-24
references: 3358796
references: Ann Rheum Dis. 2010 May;69(5):817-21
references: 19581278
references: Lancet. 2004 Feb 28;363(9410):675-81
references: 15001324
references: Curr Rheumatol Rep. 1999 Dec;1(2):157-63
references: 11123030
references: J Rheumatol. 2003 Dec;30(12):2563-71
references: 14719195
references: Arthritis Rheum. 1995 Jan;38(1):44-8
references: 7818570
references: Ann Intern Med. 2006 Jun 20;144(12):865-76
references: 16785475